AstraZeneca has laid out a host of new manufacturing projects in recent months, including new biologics plants in Europe and the U.S. But while those projects are in the works, it has a new tablet plant in Russia that has just gone online.
U.S.-based Abbott Laboratories is among a number of companies that hope to leverage acquisitions in Russia into exports, with other players such as India's Lupin among other potential firms to look to ship wider abroad.
Orthopedics player Smith & Nephew is rounding out its presence in emerging markets with the acquisition of the trauma and orthopedics business as well as a manufacturing company of the DeOst Group. The Russian company manufactures medical devices and has also served as Smith & Nephew's product distributor in the region since 2009.
Lupin Pharmaceuticals has made no secret of its intention to grow through acquisitions at home and abroad and last week announced it would make a major buy of Russian generic drug maker ZAO Biocom, placing it in a turbulent but fast-growing market.
Russia's Generium has started construction in the Vladimir region on what is being billed as Europe's largest biopharmaceutical plant.
Two key executives of Novartis AG subsidiary Alcon with responsibility for Asia were fired this week, AsianScientist reported, after confirming the action by the parent company.
Moscow is opening a gray market to allow imports of drugs intended for sale in other countries to be sold in Russia without the consent of the maker with a trademark for the product. The government hopes the move will lower pharmaceutical costs.
A report by Deutsche Welle says roughly half of the prescription drugs sold online are fake, and Russia is quickly becoming a major source of bogus medications.
China and Russia have become new targets for compulsory-licensing campaigns as an activist group widens its global challenge to Gilead's expensive Sovaldi (sofosbuvir) hepatitis C drug.
Back in the 1980s, the decade of Russia's failed occupation of Afghanistan, the Soviet military developed a novel way of treating blood clots, with trombovazima. Now, Russia's Biotechnopark in Koltsovo is producing tablets and injectables of the "Afghan drug" for the market.